“Serotonergic analgesic therapy based on5-HT7 receptor agonist (STEP7)” is a project constituting a part of our innovative pipeline, implemented in the field of neuropsychiatry.
The goal of the STEP7 project is the development and clinical evaluation up to and including phase II studies, of a first-in-class 5-HT7 receptor agonist as an analgesic used in treatment of neuropathy, which is a major clinical issue and a huge socioeconomic burden. Experts estimate that neuropathic pain will affect an increasing number of people, as it accompanies other conditions characterised by increasing prevalence, such as diabetes, shingles, HIV infection, stroke and multiple sclerosis.
In accordance with the subsidy agreement, the total cost of the project is PLN 55.6 million, and the subsidy awarded is PLN 31.2 million.
The period of eligibility of the project costs ends on 31 December 2023.